BioCentury | May 23, 2017
Distillery Techniques

Drug platforms

...thermostabilizing sites in PAR2, one glycosylation site and N-terminal and C-terminal truncations. Crystallographic analyses and molecular simulations...
BioCentury | Apr 15, 2013
Company News

MDL Information Systems Inc. management update

...Rudolph Potenzone, as VP chemical technologies; formerly responsible for scientific and chemical applications at Polygen/ Molecular Simulations Inc. WIR...
BioCentury | Apr 15, 2013
Company News

Molecular Simulations Inc, Zymark Corp deal

...Zymark will integrate its robotic high throughput screening workstations with Molecular Simulations' analysis tools for combinatorial chemistry...
...structure-activity relationships that can be used to give feedback into the design of compound libraries. Molecular Simulations...
BioCentury | Apr 15, 2013
Company News

Molecular Simulations other research news

...grant from the General Medical Sciences agency to develop computer-aided molecular design for nucleic acids. Molecular Simulations Inc....
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., Molecular Simulations deal

...which users have access to 3-D structure prediction Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. Molecular Simulations Inc....
BioCentury | Sep 26, 2011
Product Development

A relationship with no attachments

Zymeworks Inc. believes its Azymetric platform for creating bispecific antibodies is better than other technologies because it can create IgG1 antibodies without linkers or attachments in a pure, stable and scalable manner. Merck & Co....
BioCentury | Jul 16, 2001
Strategy

Pharmacopeia: Success was fleeting

...for service basis. In addition, through a series of acquisitions starting with the purchase of Molecular Simulations Inc....
BioCentury | Jul 16, 2001
Strategy

Pharmacopeia: Success was fleeting

...for service basis. In addition, through a series of acquisitions starting with the purchase of Molecular Simulations Inc....
BioCentury | May 14, 2001
Company News

Senomyx management update

...Saiid Zarrabian as president and COO, formerly COO at Pharmacopeia Inc. and president of Pharmacopeia's Molecular Simulations...
BioCentury | May 8, 2001
Company News

Senomyx names new president

...as president and COO. Prior, he was COO at Pharmacopeia (PCOP) and president of PCOP's Molecular Simulations...
Items per page:
1 - 10 of 70
BioCentury | May 23, 2017
Distillery Techniques

Drug platforms

...thermostabilizing sites in PAR2, one glycosylation site and N-terminal and C-terminal truncations. Crystallographic analyses and molecular simulations...
BioCentury | Apr 15, 2013
Company News

MDL Information Systems Inc. management update

...Rudolph Potenzone, as VP chemical technologies; formerly responsible for scientific and chemical applications at Polygen/ Molecular Simulations Inc. WIR...
BioCentury | Apr 15, 2013
Company News

Molecular Simulations Inc, Zymark Corp deal

...Zymark will integrate its robotic high throughput screening workstations with Molecular Simulations' analysis tools for combinatorial chemistry...
...structure-activity relationships that can be used to give feedback into the design of compound libraries. Molecular Simulations...
BioCentury | Apr 15, 2013
Company News

Molecular Simulations other research news

...grant from the General Medical Sciences agency to develop computer-aided molecular design for nucleic acids. Molecular Simulations Inc....
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., Molecular Simulations deal

...which users have access to 3-D structure prediction Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. Molecular Simulations Inc....
BioCentury | Sep 26, 2011
Product Development

A relationship with no attachments

Zymeworks Inc. believes its Azymetric platform for creating bispecific antibodies is better than other technologies because it can create IgG1 antibodies without linkers or attachments in a pure, stable and scalable manner. Merck & Co....
BioCentury | Jul 16, 2001
Strategy

Pharmacopeia: Success was fleeting

...for service basis. In addition, through a series of acquisitions starting with the purchase of Molecular Simulations Inc....
BioCentury | Jul 16, 2001
Strategy

Pharmacopeia: Success was fleeting

...for service basis. In addition, through a series of acquisitions starting with the purchase of Molecular Simulations Inc....
BioCentury | May 14, 2001
Company News

Senomyx management update

...Saiid Zarrabian as president and COO, formerly COO at Pharmacopeia Inc. and president of Pharmacopeia's Molecular Simulations...
BioCentury | May 8, 2001
Company News

Senomyx names new president

...as president and COO. Prior, he was COO at Pharmacopeia (PCOP) and president of PCOP's Molecular Simulations...
Items per page:
1 - 10 of 70